GSK2618960 / GSK - LARVOL DELTA

Characterization of the robust humoral immune response to GSK2618960, a humanized anti-IL-7 receptor monoclonal antibody, observed in healthy subjects in a Phase 1 study. (PubMed, PLoS One) - "GSK2618960 treatment of PBMCs increased the proportion of DC cells showing an increase in expression of CD83, CD86 and CD209, which indicated enhanced DC differentiation and activation relative to the isotype control anti-β amyloid antibody. Collectively, the evidence supports that the high incidence of observed clinical immunogenicity was likely related to the receptor-mediated activity by GSK2618960."

Clinical • Journal • P1 data • Immunology • CD4 • IL7

Single Ascending Doses Study of Anti- Interleukin-7 Receptor α Monoclonal Antibody (GSK2618960) in Healthy Volunteers (clinicaltrials.gov) - P1; N=18; Completed; Sponsor: GlaxoSmithKline; Active, not recruiting ➔ Completed

Trial completion • Biosimilar • Immunology • Inflammation

Anti-IL-7 receptor α monoclonal antibody (GSK2618960) in healthy subjects - a randomised, double-blind placebo-controlled study. (PubMed, Br J Clin Pharmacol) - "GSK2618960 was well tolerated and blocked IL-7 receptor signalling upon full target engagement. Although there was no discernible impact on peripheral T cell subsets in healthy subjects, GSK2618960 may effectively modulate auto-inflammatory activity of pathogenic T cells in diseased tissue. A relatively short half-life likely results from target-mediated rather than ADA-mediated clearance."

Clinical • Journal